Drugs Controller General of India (DCGI) has approved multinational pharmaceutical company Cipla`s request of import and marketing of Moderna`s COVID-19 vaccine for restricted emergency use in India.
Drugs Controller General of India (DCGI) has approved multinational pharmaceutical company Cipla`s request of import and marketing of Moderna`s COVID-19 vaccine for restricted emergency use in India.
Cipla on Monday applied for permission to import Moderna COVID-19 vaccines citing DCGI notices on April 15 and June 1 that the vaccine could be sold without testing if the USFDA approves it for the European Union. The vaccine has already been authorised by WHO for emergency use.
Cipla has requested import and marketing authorization of these jabs on behalf of a US pharma company.
Moderna and Pfizer are among the companies that appealed to the Indian government to do away with the requirement of local trials after allowing emergency use.
Cipla/Moderna gets DCGA (Drugs Controller General of India) nod for import of #COVID19 vaccine, Government to make an announcement soon: Sources pic.twitter.com/zsAIo6y70s
— ANI (@ANI) June 29, 2021
Moderna Covid-19 vaccine has been developed by Moderna, which is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It showed an efficacy of more than 90% in clinical trials and it is effective against Covid-19 Delta variants.
Your support to NYOOOZ will help us to continue create and publish news for and from smaller cities, which also need equal voice as much as citizens living in bigger cities have through mainstream media organizations.